Paratek Pharmaceuticals (PRTK) Share Price Rose While Brown Brothers Harriman & Co Trimmed Its Position; Tekla Capital Management Has Cut Its Exelixis (EXEL) Position by $3.91 Million; Market Value Declined

January 4, 2018 - By Michael Collier

Brown Brothers Harriman & Co decreased its stake in Paratek Pharmaceuticals Inc (PRTK) by 21.74% based on its latest 2017Q3 regulatory filing with the SEC. Brown Brothers Harriman & Co sold 80,000 shares as the company’s stock rose 33.85% with the market. The institutional investor held 287,902 shares of the health care company at the end of 2017Q3, valued at $7.23 million, down from 367,902 at the end of the previous reported quarter. Brown Brothers Harriman & Co who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be less bullish one the $522.50M market cap company. The stock decreased 0.27% or $0.05 during the last trading session, reaching $18.7. About 429,663 shares traded or 22.95% up from the average. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has risen 62.03% since January 4, 2017 and is uptrending. It has outperformed by 45.33% the S&P500.

Tekla Capital Management Llc decreased its stake in Exelixis Inc. (EXEL) by 29.52% based on its latest 2017Q3 regulatory filing with the SEC. Tekla Capital Management Llc sold 162,825 shares as the company’s stock declined 14.88% while stock markets rallied. The institutional investor held 388,822 shares of the health care company at the end of 2017Q3, valued at $9.42M, down from 551,647 at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Exelixis Inc. for a number of months, seems to be less bullish one the $9.39B market cap company. The stock increased 1.11% or $0.35 during the last trading session, reaching $31.75. About 2.67M shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 266.48% since January 4, 2017 and is uptrending. It has outperformed by 249.78% the S&P500.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 24 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Thursday, June 15 by Leerink Swann. Wedbush maintained the shares of PRTK in report on Tuesday, April 4 with “Outperform” rating. The stock has “Buy” rating by Cantor Fitzgerald on Monday, June 5. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Outperform” rating by Robert W. Baird on Friday, May 13. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, July 17. On Saturday, August 8 the stock rating was downgraded by Zacks to “Hold”. The company was maintained on Wednesday, August 23 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, June 29. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Sell” rating given on Friday, August 14 by Zacks. As per Thursday, July 23, the company rating was initiated by Gabelli.

Investors sentiment decreased to 1.54 in 2017 Q3. Its down 0.35, from 1.89 in 2017Q2. It is negative, as 17 investors sold PRTK shares while 29 reduced holdings. 33 funds opened positions while 38 raised stakes. 20.11 million shares or 4.43% more from 19.26 million shares in 2017Q2 were reported. Rainier Ltd Liability Co reported 78,920 shares. Federated Investors Incorporated Pa reported 35,428 shares. The Germany-based Deutsche Bankshares Ag has invested 0.01% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Sei Invs holds 0% or 8,981 shares in its portfolio. American Intl Gru owns 15,804 shares. General Amer has 347,213 shares for 0.83% of their portfolio. Numeric Limited Co stated it has 0.04% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Millennium Limited Liability Co holds 334,353 shares or 0.01% of its portfolio. Prelude Capital Mngmt Ltd Liability holds 0.05% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 20,606 shares. Credit Suisse Ag owns 38,092 shares. Eam Ltd Liability Corporation stated it has 77,885 shares or 0.26% of all its holdings. Next Financial holds 0% or 73 shares. Art Advsrs Limited owns 14,537 shares. Suffolk Cap Mgmt Limited Liability reported 69,305 shares. Davidson Kempner Capital Lp holds 0.2% or 268,001 shares in its portfolio.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on March, 1. They expect $-0.72 EPS, up 37.93% or $0.44 from last year’s $-1.16 per share. After $-0.77 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.49% EPS growth.

Brown Brothers Harriman & Co, which manages about $12.77 billion and $18.77B US Long portfolio, upped its stake in Qualcomm Inc (NASDAQ:QCOM) by 40,644 shares to 9.03M shares, valued at $468.11M in 2017Q3, according to the filing. It also increased its holding in Perrigo Company Plc (NYSE:PRGO) by 570,187 shares in the quarter, for a total of 5.21M shares, and has risen its stake in Discovery Communications (NASDAQ:DISCK).

Investors sentiment decreased to 1.23 in 2017 Q3. Its down 0.10, from 1.33 in 2017Q2. It is negative, as 39 investors sold EXEL shares while 64 reduced holdings. 51 funds opened positions while 76 raised stakes. 237.25 million shares or 3.37% more from 229.51 million shares in 2017Q2 were reported. Winch Advisory Services Limited Liability Co invested in 500 shares. Citigroup holds 101,272 shares or 0% of its portfolio. Millennium Mgmt Ltd Liability Com accumulated 1.46 million shares. Principal Fin Grp holds 48,595 shares. Cwm Limited Co owns 168 shares for 0% of their portfolio. California Employees Retirement System owns 663,539 shares or 0.02% of their US portfolio. Icon Advisers Incorporated, Colorado-based fund reported 32,000 shares. Ubs Asset Americas holds 1.49 million shares. Insight Mgmt has 50,818 shares. Cambridge Invest Advsrs holds 17,075 shares. Bankshares Of America De invested 0% in Exelixis, Inc. (NASDAQ:EXEL). Wetherby Asset Mngmt Incorporated holds 8,298 shares. Voya Ltd Limited Liability Company holds 0.08% or 1.60M shares. 286,284 were accumulated by Guggenheim Limited Liability. Hillsdale invested 0.24% in Exelixis, Inc. (NASDAQ:EXEL).

Analysts await Exelixis, Inc. (NASDAQ:EXEL) to report earnings on February, 26. They expect $0.12 earnings per share, 0.00% or $0.00 from last year’s $0.12 per share. EXEL’s profit will be $35.50 million for 66.15 P/E if the $0.12 EPS becomes a reality. After $0.26 actual earnings per share reported by Exelixis, Inc. for the previous quarter, Wall Street now forecasts -53.85% negative EPS growth.

Since September 12, 2017, it had 0 insider purchases, and 8 sales for $23.92 million activity. 60,640 Exelixis, Inc. (NASDAQ:EXEL) shares with value of $1.65 million were sold by Haley Patrick J.. $5.54 million worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by PAPADOPOULOS STELIOS on Monday, September 18. Another trade for 100,000 shares valued at $2.68 million was sold by Senner Christopher J.. Hessekiel Jeffrey also sold $663,018 worth of Exelixis, Inc. (NASDAQ:EXEL) on Wednesday, September 27. WILLSEY LANCE sold $2.69 million worth of stock. $2.38M worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by Schwab Gisela.

Among 11 analysts covering Exelixis (NASDAQ:EXEL), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Exelixis had 35 analyst reports since January 19, 2016 according to SRatingsIntel. Stifel Nicolaus upgraded the stock to “Buy” rating in Monday, April 4 report. The firm earned “Hold” rating on Monday, June 19 by Oppenheimer. The firm has “Buy” rating by Piper Jaffray given on Wednesday, August 16. The stock of Exelixis, Inc. (NASDAQ:EXEL) earned “Hold” rating by Stifel Nicolaus on Monday, October 16. The firm has “Hold” rating given on Tuesday, February 28 by Stifel Nicolaus. The stock has “Buy” rating by J.P. Morgan on Friday, July 21. The firm earned “Buy” rating on Thursday, July 13 by SunTrust. The company was maintained on Wednesday, August 2 by Piper Jaffray. The stock of Exelixis, Inc. (NASDAQ:EXEL) earned “Hold” rating by Oppenheimer on Monday, July 10. As per Monday, June 12, the company rating was initiated by Oppenheimer.

Tekla Capital Management Llc, which manages about $1.06B and $2.80 billion US Long portfolio, upped its stake in Wright Medical Group N.V. by 52,000 shares to 266,781 shares, valued at $6.90M in 2017Q3, according to the filing. It also increased its holding in Johnson & Johnson (NYSE:JNJ) by 84,570 shares in the quarter, for a total of 798,932 shares, and has risen its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).